Related Experiment Video
Updated: Dec 13, 2025

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Novel Approaches to the Systemic Management of Uveal Melanoma
Shaheer Khan1, Richard D Carvajal2,3
1Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, New York, NY, 10032, USA. sk4488@cumc.columbia.edu.
Purpose Of Review:
Uveal melanoma is a distinct subtype of melanoma characterized by a unique biology and divergent response to immune therapies. In this review, we will discuss our current understanding of the pathophysiology of uveal melanoma, systemic treatment options for advanced disease, and potential future therapeutic directions.
Recent Findings:
Although treatment with single-agent checkpoint blockade has been generally disappointing, the results of combined checkpoint blockade are modestly more promising. Several alternative systemic therapeutic approaches have been or are currently being investigated, including two agents that have been taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor. Treatment of advanced uveal melanoma remains challenging, however, encouraging results from novel agents offer hope for improvement in the near future.
Insights
Uveal melanoma treatment remains challenging, but novel therapies show promise. This review covers pathophysiology, current systemic options for advanced disease, and future directions for uveal melanoma.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Uveal melanoma is a rare eye cancer with unique biology.
- It shows a distinct response to immune therapies.
- Advanced disease treatment options are limited.
Purpose of the Study:
- To review the pathophysiology of uveal melanoma.
- To discuss current systemic treatment options for advanced uveal melanoma.
- To explore potential future therapeutic directions.
Main Methods:
- Literature review of current understanding and research.
- Analysis of systemic treatment options, including checkpoint blockade.
- Evaluation of novel agents like tebentafusp and IDE196.
Main Results:
- Single-agent checkpoint blockade has shown limited efficacy.
- Combined checkpoint blockade offers modest promise.
- Novel agents like tebentafusp and IDE196 are under investigation.
Conclusions:
- Advanced uveal melanoma treatment is challenging.
- Emerging therapies offer hope for improved outcomes.
- Continued research into novel agents is crucial.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistant Cancers
Glaucoma: Overview

